Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens.

AIDS (London, England) - 1 Jun 2026

Marcelin Anne-Geneviève, Soulie Cathia, Wirden Marc, Gruber Joshua, Prata Menezes Neia, Lim Travis, Barriere Guillaume, Descamps Diane, Charpentier Charlotte, Calvez Vincent

Abstract excerpt

OBJECTIVE: To assess the prevalence and patterns of treatment-emergent resistance-associated mutations (RAMs) in people with HIV (PWH) with ≥1 prior regimen experiencing virologic failure (VF) with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), dolutegravir/lamivudine (DTG/3TC), or cabotegravir/rilpivirine (CAB + RPV) in an observational setting. DESIGN: A noninterventional, multicenter,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to France

Share to HIV Infections

Share to Prevalence

Share to Treatment Failure

Share to Viral Load

Source

Open in PubMed Open full text

Identifiers

PMID: 41467692
DOI: 10.1097/QAD.0000000000004438
PMCID: PMC13152064

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiretroviral resistance in at least second-line HIV-1 treatment virologic failure with common InSTI-based regimens.PMID 41467692Read ↗

Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study.Semantic proximity Read ↗

Virological failure and resistance emergence during treatment with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir/lamivudine in people living with HIV without prior resistance mutations: a real-world study.Semantic proximity Read ↗

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review.Semantic proximity Read ↗

Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.Semantic proximity Read ↗

Worrisome Emergence of Pan-INSTI Resistance: A Systematic Scoping Review of Dolutegravir Resistance in INSTI-Naïve Patients Post-Therapy FailureSemantic proximity Read ↗

Factors associated with virological failure in people with HIV treated with bictegravir/emtricitabine/tenofovir alafenamide. Impact of pre-existing mutations and risk of resistance emergence. ANRS-CO3-AquiVIH-NA cohort.Semantic proximity Read ↗

HIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studiesSemantic proximity Read ↗

HIV-1 virologic failure in the RESINA cohort: lessons from two decades of real-world data.Semantic proximity Read ↗

Risk of Emergent Dolutegravir Resistance Mutations In People Living With HIV: A Rapid Scoping ReviewSemantic proximity Read ↗

HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018–2024Semantic proximity Read ↗

Analysis of the Virological Failure Rates and Influencing Factors of ART Regimens Containing Integrase Inhibitors: A Retrospective Analysis from the Real World in ChongqingSemantic proximity Read ↗

Emergent drug resistance with integrase strand transfer inhibitor-based regimensSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.